Effects of Quercetin on Cardiometabolic Outcomes

U

University of Central Lancashire

Status

Not yet enrolling

Conditions

Cardiometabolic Syndrome

Treatments

Dietary Supplement: Quercetin
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT06230861
Quercetin cardiometabolic

Details and patient eligibility

About

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Enrollment

36 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy
  • Between 18 & 65 years
  • Non-smoker
  • BMI < 30
  • Able to give informed consent

Exclusion criteria

  • Pregnancy
  • Diabetes or any other metabolic/ uncontrolled hypertensive conditions
  • Food allergies to quercetin
  • Habitual consumption of quercetin
  • Not regularly taking medication or antioxidant supplements

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

36 participants in 2 patient groups, including a placebo group

Quercetin tablets 500mg 1 x pe
Experimental group
Description:
Quercetin tablets 500mg 1 x per day
Treatment:
Dietary Supplement: Quercetin
Placebo
Placebo Comparator group
Treatment:
Other: Placebo

Trial contacts and locations

0

Loading...

Central trial contact

Jonathan Sinclair, PhD, DSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems